



Potential Combination of Probiotic Lactobacillus reuteri Encapsulated High Internal Phase Emulsion (HIPE)-Alginate and Modulation of Thylakoid-Based **Prebiotic Diets: Alternative Prevention Strategies** for Atherosclerosis

I Gede Krisna Arim Sadeva: Jennifer Louisa: Putri Ayu Wulandari Faculty of Medicine, Udayana University


BACKGROUND

Atherosclerosis is characterized by an atheroma that lines the vascular lumen and is highly susceptible to thrombosis and obstruction of tissue perfusion, which subsequently causes ischemia. This condition plays a significant role in the development of peripheral, cerebral, and coronary artery diseases. Atherosclerosis has one of the highest morbidity and mortality rate amongst all cardiovascular diseases globally. The existing long-term preventive measures are considered less than optimal, due to their cost, numerous significant side effects, and the patients' increasingly high demand for natural options in healthcare. Accordingly, utilization of probiotic and prebiotic agent as a preventive approach and/or definitive treatment has been developed, seeing its promising potential, low cost, and minimal side effect.

Aim of the review

To investigate the potential of the combination of HIPE-alginate encapsulated probiotic L. reuteri with thylakoid-based diet modulation as a preventive measure against atherosclerosis.

METHODS



48 suitable studies were obtained as the main references. All studies were then critically reviewed in terms of validity, importance, and applicability. The types of data obtained are both qualitative and quantitative, thus may be compared and further analyzed.

English or Indonesian.

MAIN REFERENCES

- Wong MCS, Zhang DX, Wang HHX. Rapid emergence of atherosolerosis in Asia A systematic review of coronary atherosoleroic heart disease epidemiology and implications for prevention and control strategies. Current Opinion in Lipidology, 2015. Singh TP, Kaur G, Malis RK, Schillinger U, Guigas C, Kapila S. Characterization of Intestinal Lactobacillus reuteri Strains as Potential Probiotics. Probiotics Antimicrob Proteins, 2012. Strabborn EL, Westforn B, Linninge C, Bonn P, Farrell M, Rehfeld JF, et al. Dietary green-plant thylakoids decrease gastric emptying and gut transit, promote changes in the gut microbial flora, but does not cause steatorrhee. Nutr Metab. 2016; Foshati S, Examzadeh M. Thylakoids: A Novel Food-Derived Supplement for Obesity-A Mini-Review. International Journal for Valantian and Nutrino Research. 2023. Singh P, Medrotrio B, Miguel MG, Esquena J, On the necapsulation and viability of probiotic bacteria in edible carboxymethyl SS, J, Cal Y, Tal K, Guo C, Zhu S, Mao L, et al. High-internal-phase emulsions (HIPEs) for co-encapsulation of probiotics and curcurin: enhanced survivability and controlled release. Food Funct. 2021: Wy Y, Zhang Q, Ren Y, Ruan Z, Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials. PLos One. 2017;12(6):1–15.

RESULT & DISCUSSION

Lactobacillus reuteri and Its Anti-atherogenic Effect

Lactobacillus sp. is a part of human's gut microflora without pathogenic tendencies. L. reuteri in particular has been found to possess anti-atherosclerotic effect through the anti-cholesterol and anti-inflammatory pathways. This strain shows the highest potential compared to other Lactobacillus species. In addition, L. reuteri has competitive advantage in its resistance and maintenance in the gastrointestinal tract. However, exposure to gastric acid and bile salts can significantly reduce the life span of these bacterias.




Table 1. Previous studies of L. reuteri effects on lipid profile of atherogenic m

Author, Year	Strain L. reuteri	Doses	Effects
Huang, 2015	263 (Lr263)	Human: 900 mg/day (lyophilized powder) or 2.1 ×10 ⁹ cells/serving/day.	↑ HDL-C and ↓ TC, TG, LDL-C, LDL-C/ HDL-C ratio, hepatic TC
Singh, 2015	LR6	Rat: 108 CFU/mL for 60 days	↓ TC, TG, and LDL
Jones, 2012	NCIMB 30242	Human: 2.9 x 10 ⁹ CFU per capsule for 9 weeks	\downarrow LDL-C by 11.64%, TC by 9.14%, non-HDL-C
Yang, 2021	FYNLJ109L1	Mice: 5 × 10 ⁹ CFU/mL for 14 weeks	↓ LDL-C and LDL-C/HDL-C
Lu, 2022	Fn041	Mice: 1 × 10 ⁹ CFU/day for 8 weeks	↓TC and LDL-C
Sun, 2020	HI120	Mice: 1.000 mg/kg daily (every 2 days after 8 weeks) for 12 weeks	↓ TC
Ting, 2015	GMNL-263	Hamster: 2.5×10^9 cells/kg per day for 8 weeks	↓ LDL-C and TC

Thylakoid and Its Anti-atherogenic Effect

Thylakoid, a component in chloroplast with functions related to photosynthesis, was discovered to affect atherosclerosis positively through fat emulsification, antioxidant pathway, and activation of peroxisome proliferator-activated receptors (PPARs). This substance may also act as a prebiotic, sustaining the survival and growth of L. reuteri in the gut by regulating appetite and food consumption.

Potential Combination of L. reuteri (Probiotic) and Thylakoidbased diet (Prebiotic)

L. reuteri and thylakoid have anti-atherogenic effects through bilesalt hydrolase enzyme secretion mechanism, immunomodification effect, regulation of cholesterol absorption, production of short chain fatty acids, increased antioxidant activity, inhibition of HMG-CoA reductase, and regulation of gut microbiota through the prebiotic effect of thylakoids. L. reuteri was found to have a significant increase in the ileal mucosa of experimental animals fed thylakoid compared to controls.



High Internal Phase Emulsion (HIPE)-alginate Encapsulation

HIPE-alginate encapsulation aims to increase the viability of probiotics in the gastrointestinal tract. HIPE refers to the process of forming an emulsion with an internal phase volume fraction of >74%. Compared to other polymeric compounds such as chitosan, alginate-based encapsulation has a significant protective effect in aiding the administration of probiotic and is non-toxic.



CONCLUSION

The combination of probiotics and prebiotics, especially L. reuteri with dietary thylakoids was reported to have a significant anti-atherogenic effect. In addition, encapsulation using HIPE-alginate in L. reuteri preparations was reported to increase the viability of probiotics and provide protection against low pH conditions in the stomach when given orally.

This review lacks studies that reported the mechanisms and interactions between probiotics and prebiotics. Thus, the safety and effectiveness of this combination therapy require further testing and investigations, especially in human clinical trials.

